Welcome to our dedicated page for ETRACS Whitney US Critical Techs ETN SEC filings (Ticker: WUCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
UBS AG filings for WUCT document foreign private issuer reporting and securities-offering disclosures for the ETRACS Whitney US Critical Technologies ETN. The record includes Form 6-K reports, Form 20-F references, IFRS consolidated financial information, capitalization disclosures, and debt and equity presentation for UBS AG and its subsidiaries.
Registration-related filings also incorporate Form F-3 materials and legal opinion exhibits for UBS AG securities offerings. These disclosures address the issuer's reporting framework, capital structure, funding from UBS Group AG, and the formal documentation supporting registered securities.
UBS AG has filed a preliminary pricing supplement for a new structured product: Trigger Autocallable Contingent Yield Notes linked to the American Depositary Receipts of Arm Holdings plc (ARM). The Notes are unsecured, unsubordinated debt of UBS AG, scheduled to price on June 20 2025, settle on June 24 2025 and mature on June 24 2026, unless called earlier. Investors will receive a contingent coupon of 14.07 %–16.07 % per annum only when the ADR’s closing level on an observation date is at or above the 60 % coupon barrier. Observation dates are monthly.
Automatic Call. If on any observation date prior to final valuation the ADR closes at or above its initial level, the Notes are automatically redeemed at par plus the contingent coupon, terminating further payments. Downside Protection. If not called, principal is protected only when the final ADR level is ≥ 60 % of the initial level (the downside threshold). Should the final level fall below that threshold, investors incur a loss equal to the full negative return of ARM ADRs and could lose their entire principal.
Key economics. Issue price is $10.00 per Note; underwriting discount is $0.125; proceeds to UBS are $9.875. UBS estimates the initial economic value at $9.54–$9.79, reflecting internal funding costs. Minimum investment is 100 Notes ($1,000). The product will not be listed on an exchange and secondary liquidity is expected to be limited. Payments depend entirely on UBS’s creditworthiness; the Notes are not FDIC-insured.
Risks highlighted. Investors face (i) credit risk of UBS, (ii) market risk equivalent to a 40 % downside buffer only at maturity, (iii) reinvestment risk if automatically called, (iv) potential illiquidity caused by the lack of listing and T+2 settlement versus the market’s T+1 norm, and (v) the possibility of receiving no coupons over the life of the security.